Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

<< Previous

Bullboard Posts

Next >>

Post by trade007on May 27, 2022 10:51am

123 Views

Post# 34712082

Hemostemix Inc. $HEM Stock is refreshed on TSX-V.

The company has the share outstanding of all classes as 68M,+ assessing the stocks for 52-weeks are viewed as 0.42 (high) and 0.13 (low), having a constant market capitalization of 23.88M marking since the past few days.

<< Previous

Bullboard Posts

Next >>

Odd Burger to add 40 locations in Florida